Sarah Dysinger
A5025086503- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Sirtuins and Resveratrol in Medicine
- CAR-T cell therapy research
- SARS-CoV-2 detection and testing
- Autophagy in Disease and Therapy
- PARP inhibition in cancer therapy
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- Cancer, Hypoxia, and Metabolism
University of Pennsylvania
2021-2023
Philadelphia University
2022
Immune memory after vaccination Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven highly effective at preventing COVID-19. However, the evolution of viral variants, and waning antibody levels over time, raise questions regarding longevity vaccine-induced immune protection. Goel et al . examined B T lymphocyte responses in individuals who received SARS-CoV-2 messenger RNA vaccines. They performed a 6-month longitudinal study never had infection...
Novel mRNA vaccines for SARS-CoV-2 have been authorized emergency use. Despite their efficacy in clinical trials, data on vaccine-induced immune responses are mostly limited to serological analyses. Here, we interrogated antibody and antigen-specific memory B cells over time 33 naïve 11 recovered subjects. individuals required both vaccine doses optimal increases antibodies, particularly neutralizing titers against the B.1.351 variant. Memory specific full-length spike protein receptor...
ABSTRACT SARS-CoV-2 mRNA vaccines have shown remarkable efficacy, especially in preventing severe illness and hospitalization. However, the emergence of several variants concern reports declining antibody levels raised uncertainty about durability immune memory following vaccination. In this study, we longitudinally profiled both cellular responses naïve recovered individuals from pre-vaccine baseline to 6 months post-mRNA Antibody neutralizing titers decayed peak but remained detectable all...
Summary The SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific analyses in healthy individuals following vaccination. Vaccination induced rapid near-maximal CD4 + responses all subjects after first vaccine dose. CD8 developed gradually second dose were variable. Vaccine-induced cells had central memory characteristics included both Tfh Th1 subsets, similar to...
Abstract Despite a clear role in protective immunity, the durability and quality of antibody memory B cell responses induced by mRNA vaccination, particularly 3 rd dose vaccine, remains unclear. Here, we examined cohort individuals sampled longitudinally for ∼9-10 months after primary 2-dose vaccine series, as well ∼3 dose. Notably, decay slowed significantly between 6- 9-months post-primary essentially stabilizing at time Antibody also continued to improve least 9 vaccination. Spike-...
Pancreatic ductal adenocarcinoma (PDAC) is classified into two key subtypes, classical and basal, with basal PDAC predicting worse survival. Using in vitro drug assays, genetic manipulation experiments, vivo studies human patient-derived xenografts (PDXs) of PDAC, we found that PDACs were uniquely sensitive to transcriptional inhibition by targeting cyclin-dependent kinase 7 (CDK7) CDK9, this sensitivity was recapitulated the subtype breast cancer. We showed cell lines, PDXs, publicly...
Abstract Pancreatic Ductal Adenocarcinoma (PDA) can be characterized by two distinct transcriptional subtypes: Classical and Basal-like. The basal PDA subtype is more aggressive has the worst overall survival. Previous work shown that Sirtuin 6 histone deacetylase (SIRT6) acts as a tumor suppressor cooperates with oncogenic KRAS in GEMM models of PDA. Our study identifies SIRT6 biomarker for investigates underlying sensitivity to inhibition cyclin dependent kinases (CDKs). Through analysis...